Hanneke Schuitemaker

Last updated
Hanneke Schuitemaker
Hanneke Schuitemaker cropped.jpg
Born1964 (age 58–59)
Netherlands
Scientific career
Institutions University of Amsterdam
Sanquin
Academic Medical Center
Crucell
Thesis Role of HIV-1 monocytotropism in AIDS pathogenesis  (1992)

Hanneke Schuitemaker is a Dutch virologist, the Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson's Janssen Vaccines & Prevention, and a Professor of Virology at the Amsterdam University Medical Center of the University of Amsterdam (since 2004). She has been involved in the development of Janssen's Ebola vaccine and is involved in the development of a universal flu vaccine, HIV vaccine, RSV vaccine and COVID-19 vaccine.

Contents

Early life and education

Schuitemaker (1964) grew up in the Netherlands. [1] Her mother was a bookkeeper and her father was an electrical engineer. [1] As a child she was fascinated by medicine, and after earning her undergraduate degree she completed a PhD programme in AIDS pathogenesis at the University of Amsterdam. [1]

Research and career

Schuitemaker started to research HIV/AIDS in 1989. [1] Whilst interested in the virus itself, Schuitemaker also wanted to learn more about the patients who suffered from the disease, and took part in a patient outreach program. Her interactions in this program strengthened her motivation to better understand the disease, help find a vaccine and treatments. She studied the pathogenesis of HIV-1 throughout her career. Her early research focussed on whether HIV could infect other cells in the body than just T cells, including cells in the brain and lungs. [1] She started working at Sanquin, the Netherlands blood supply foundation based in Amsterdam, where she was made Head of the department of Clinical Viro-Immunology in 1998. Schuitemaker has been involved in policy, and has held advisory positions on several vaccine charities. From 2003 to 2004, she was a visiting scientist at the La Jolla Scripps Research Institute. [2]

Schuitemaker joined the Academic Medical Center in Amsterdam in 2008, where she was made Chair of Experimental Immunology. [2] She moved to Crucell in 2010, which, at the time, was an independent biotechnology company. [3] Two weeks later, Crucell was acquired by Janssen Vaccines, part of Johnson & Johnson. [3] She was appointed Global Head of Viral Vaccines Discovery and Translational Medicine. [4] At Janssen, Schuitemaker worked on the universal flu vaccine. [5] She returned to working on vaccinations to protect against HIV-1. [6] Schuitemaker demonstrated the efficacy of the adenovirus/protein vaccines against simian immunodeficiency virus in rhesus macaques. [7] [8] In 2018, Schuitemaker's vaccine regime was shown to induce an immune response to HIV in humans. [1] [9] Results of Imbokodo, an investigation into the potential for this vaccine to save the lives of thousands of young women in Sub-Saharan Africa, are expected in 2021. [1] [10] Another study, Mosaico, will see 3,800 individuals taking part in a Phase 3 clinical trial of the vaccine. [11]

During the COVID-19 pandemic Janssen looked to develop a COVID-19 vaccine. [12] [13] [14] [15] Their approach started with a single viral genome, which was being tested as of March 2020. [12] Schuitemaker estimated that it would take between 12 and 18 months to manufacture a vaccine. [12] [16]

Early in the COVID-19 pandemic, Schuitemaker announced Johnson & Johnson's ambition to develop a vaccine against the unknown infectious disease. Her team's approach started with the discovery of the genetic code of SARS-CoV-2, the cause of the disease COVID-19. The various vaccine candidates have been tested from March 2020. In mid-May, she announced that Janssen's most hopeful vaccine variant will be tested on humans in July 2020. In November 2020, Jansen Vaccines announced that the production of the COVID vaccine was delayed by several months due to the occurrence of an unknown disease in one test subject in phase 3. The US regulator FDA approved the Johnson & Johnson COVID-19 vaccine for use on February 27, 2021. Approval by the European Medicines Agency was given on March 11.

Selected publications

Personal life

Schuitemaker has three sons. [2]

Related Research Articles

<span class="mw-page-title-main">Zoonosis</span> Disease that can be transmitted from other species to humans

A zoonosis or zoonotic disease is an infectious disease of humans caused by a pathogen that can jump from a non-human to a human and vice versa.

<span class="mw-page-title-main">Janssen Pharmaceuticals</span> Belgian pharmaceutical company

<span class="mw-page-title-main">Janssen Vaccines</span> Biotechnology subsidiary of Johnson & Johnson

<span class="mw-page-title-main">Rudi Pauwels</span> Belgian pharmacologist and entrepreneur

Rudi Pauwels is a Belgian pharmacologist and biotech entrepreneur.

<span class="mw-page-title-main">Antibody-dependent enhancement</span> Antibodies rarely making an infection worse instead of better

Antibody-dependent enhancement (ADE), sometimes less precisely called immune enhancement or disease enhancement, is a phenomenon in which binding of a virus to suboptimal antibodies enhances its entry into host cells, followed by its replication. The suboptimal antibodies can result from natural infection or from vaccination. ADE may cause enhanced respiratory disease, but is not limited to respiratory disease. It has been observed in HIV, RSV virus and Dengue virus and is monitored for in vaccine development.

<span class="mw-page-title-main">Jaap Goudsmit</span>

Jaap Goudsmit is Dutch scientist, known for his research in the field of AIDS and influenza. He shifted his research interest to aging and neurodegenerative diseases, like Alzheimer's Disease. He is also a prolific writer of non-fiction books: Viral Sex, the Nature of AIDS (1997); Viral Fitness, the Next SARS and West Nile in the Making (2004); Serendipity Manual (2012); The Vaccine Bug, a personal history of the World of Immunity (2013); Immorbidity Alphabet, Spelling-out a life free of dis-ease (2015); The Time of your Life, Staying healthy to the End (2016) and The Art of Facing Mortality, a scientist's view (2016).

<span class="mw-page-title-main">Robert R. Redfield</span> American medical researcher and CDC director

Robert Ray Redfield Jr. is an American virologist who served as the Director of the U.S. Centers for Disease Control and Prevention and the Administrator of the Agency for Toxic Substances and Disease Registry from 2018 to 2021.

<span class="mw-page-title-main">Bavarian Nordic</span> Pharmaceutical company

Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm. The company has a research and development facility in Martinsried, Germany, and offices in Zug, Switzerland, and Morrisville, North Carolina. The company uses viral vectors in its research and development.

<span class="mw-page-title-main">Deborah Birx</span> American physician and diplomat

Deborah Leah Birx is an American physician and diplomat who served as the White House Coronavirus Response Coordinator under President Donald Trump from 2020 to 2021. Birx specializes in HIV/AIDS immunology, vaccine research, and global health. Starting in 2014, she oversaw the implementation of the President's Emergency Plan for AIDS Relief (PEPFAR) program to support HIV/AIDS treatment and prevention programs in 65 countries. From 2014-2020, Birx was the United States global AIDS coordinator for presidents Barack Obama and Donald Trump and served as the United States special representative for global health diplomacy between 2015 and 2021. Birx was part of the White House Coronavirus Task Force from February 2020 to January 2021. In March 2021, Birx joined ActivePure Technology as Chief Medical and Science Advisor.

Vaccine shedding is a form of viral shedding which can occur following a viral infection caused by an attenuated vaccine, which is a specific vaccine technology that uses an attenuated form of a live virus. Illness in others resulting from transmission through this type of viral shedding is rare. A large proportion of vaccines are not attenuated vaccines, and therefore cannot cause vaccine-induced viral shedding.

<span class="mw-page-title-main">Bette Korber</span> American computational biologist

Bette Korber is an American computational biologist focusing on the molecular biology and population genetics of the HIV virus that causes infection and eventually AIDS. She has contributed heavily to efforts to obtain an effective HIV vaccine. She created a database at Los Alamos National Laboratory that has enabled her to design novel mosaic HIV vaccines, one of which is currently in human testing in Africa. The database contains thousands of HIV genome sequences and related data.

<span class="mw-page-title-main">Sarah Gilbert</span> English vaccinologist (born 1962)

Dame Sarah Catherine Gilbert FRS is an English vaccinologist who is a Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech. She specialises in the development of vaccines against influenza and emerging viral pathogens. She led the development and testing of the universal flu vaccine, which underwent clinical trials in 2011.

<span class="mw-page-title-main">Vaxart</span> American biotechnology company based in San Francisco

Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker.

Marylyn Martina Addo is a German infectiologist who is a Professor and the German Center for Infection Research (DZIF) Head of Infectious Disease at the University Medical Center Hamburg-Eppendorf. Addo has developed and tested vaccinations that protect people from Ebola virus disease and the MERS coronavirus EMC/2012. She is currently developing a viral vector based COVID-19 vaccine.

Allison Joan McGeer is a Canadian infectious disease specialist in the Sinai Health System, and a professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. She also appointed at the Dalla Lana School of Public Health and a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute, and is a partner of the National Collaborating Centre for Infectious Diseases. McGeer has led investigations into the severe acute respiratory syndrome outbreak in Toronto and worked alongside Donald Low. During the COVID-19 pandemic, McGeer has studied how SARS-CoV-2 survives in the air and has served on several provincial committees advising aspects of the Government of Ontario's pandemic response.

Helen Branswell is a Canadian infectious diseases and global health reporter at Stat News. Branswell spent fifteen years as a medical reporter at The Canadian Press, where she led coverage of the Ebola, Zika, SARS and swine flu pandemics. She joined Stat News at its founding 2015, leading the website's coverage of the ongoing COVID-19 pandemic.

Natalie E. Dean is an American biostatistician specializing in infectious disease epidemiology. Dean is currently an assistant professor of Biostatistics at the University of Florida. Her research involves epidemiological modeling of outbreaks, including Ebola, Zika and COVID-19.

Helen Y. Chu is an American immunologist who is an assistant professor of medicine at the University of Washington. Her research considers maternal immunization, with a focus on influenza and respiratory syncytial virus. During the COVID-19 pandemic, Chu was the first physician to recognise community transmission of the coronavirus disease within the United States.

Plandemic are a trilogy of conspiracy theory video and films produced by Mikki Willis promoting misinformation about the COVID-19 pandemic. They feature Judy Mikovits, a discredited American researcher described as an anti-vaccine activist. The first video, Plandemic: The Hidden Agenda Behind Covid-19, was released on May 4, 2020, under Willis' production company Elevate Films. The second film, Plandemic Indoctornation, which includes more interviewees, was released on August 18 by Brian Rose's conspiracy distributor London Real. Later on June 3, 2023, Plandemic 3: The Great Awakening was released on The Highwire, a conspiracy website run by anti-vaccine activist Del Bigtree.

<span class="mw-page-title-main">Viral vector vaccine</span> Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.

References

  1. 1 2 3 4 5 6 7 "Meet a Johnson & Johnson Researcher Poised to Crack the HIV Vaccine Code". Content Lab U.S. 2018-07-23. Retrieved 2020-03-22.
  2. 1 2 3 "Hanneke Schuitemaker". ECSJ2017. 2017-06-25. Archived from the original on 2020-03-22. Retrieved 2020-03-22.
  3. 1 2 Schofield, Amy (2018-03-14). "Women of pharma: Hanneke Schuitemaker". Pharmafield. Retrieved 2020-03-22.
  4. ↑ "MENS #11: Hanneke Schuitemaker". Vrij Nederland (in Dutch). 2020-01-30. Retrieved 2020-03-22.
  5. ↑ Sample, Ian; editor, science (2015-08-24). "Universal flu vaccine a step closer as scientists create experimental jabs". The Guardian. ISSN   0261-3077 . Retrieved 2020-03-22.{{cite news}}: |last2= has generic name (help)
  6. ↑ Ramsey, Lydia. "9 dangerous diseases that could be prevented by vaccines within the next decade, from HIV to cancer". Business Insider. Retrieved 2020-03-22.
  7. ↑ Barouch, Dan H.; Alter, Galit; Broge, Thomas; Linde, Caitlyn; Ackerman, Margaret E.; Brown, Eric P.; Borducchi, Erica N.; Smith, Kaitlin M.; Nkolola, Joseph P.; Liu, Jinyan; Shields, Jennifer (2015-07-17). "Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys". Science. 349 (6245): 320–324. Bibcode:2015Sci...349..320B. doi:10.1126/science.aab3886. ISSN   0036-8075. PMC   4653134 . PMID   26138104.
  8. ↑ Poli, Guido (2018-07-16). "Un vaccino antiHIV, sogno o realtà?". Scienza in rete (in Italian). Retrieved 2020-03-22.
  9. ↑ "Johnson & Johnson is about to test an experimental HIV vaccine on thousands of people". Los Angeles Times. 2019-07-12. Retrieved 2020-03-22.
  10. ↑ "Once feared HIV drug gets WHO nod". The East African. Archived from the original on 2020-02-12. Retrieved 2020-03-22.
  11. ↑ ""MOSAIC" HIV Vaccine to be Tested in Thousands Globally". Biopharma from Technology Networks. Retrieved 2020-03-22.
  12. 1 2 3 McKie, Robin (2020-03-21). "Vaccine scientist: 'Everything is so new in dealing with this coronavirus'". The Observer. ISSN   0029-7712 . Retrieved 2020-03-22.
  13. ↑ "Johnson & Johnson tests 10 variants of coronavirus vaccine". Nikkei Asian Review. Retrieved 2020-03-22.
  14. ↑ Lee, Georgina (17 March 2020). "FactCheck: how close are we to a vaccine or cure for coronavirus?". Channel 4 News. Retrieved 2020-03-22.
  15. ↑ Andy Extance2020-02-11T14:30:00+00:00. "The race to fight coronavirus". Chemistry World. Retrieved 2020-03-22.
  16. ↑ Belluz, Julia (2020-03-04). "A simple guide to the vaccines and drugs that could fight coronavirus". Vox. Retrieved 2020-03-22.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.